CVC/FOF  Sanofi-Genzyme Bioventures

http://sanofigenzymebioventures.com/





     Office Locations:

500 Kendall Street
Cambridge, MA 02142
Phone: 617-252-7500
Fax: 617-252-7600

 

Stages:

  • Early
  • Expansion
  • Growth
  • Seed


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Sanofi-Genzyme BioVentures (SGBV) is the corporate venture capital arm of Sanofi. Previously known as Genzyme Ventures, SGBV has an expanded mandate to invest across the broad business footprint of Sanofi. SGBV only invests in early stage companies with promising new products that may be future Sanofi pipeline candidates. Today, SGBV has assembled a portfolio of direct equity investments in a variety of promising innovative life-science companies. In addition to engaging in venture capital, SGBV provides transaction support for equity investments made by other groups within Sanofi, including business development and co-leading with Sunrise negotiations for Sunrise opportunities within global R&D.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Ann DeWitt Sr. Director of Investments and Principal
    Bernard Davitian VP, Managing Director
    Jason Hefler Senior Director of Investments and Principal

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      07/20/2017


      NeuroVia


      MA


      $14,000,000


      Series A


     

    Portfolio companies include:


      Common Sensing
        web link


      Edimer Pharmaceuticals
        web link


      Esperance Pharmaceuticals
        web link


      Evidation Health
        web link


      Fate Therapeutics
        web link


      GlycoMimetics
        web link


      Immune Design
        web link


      ImmuneXcite
        web link


      Kahr Medical
        web link


      LTI
        web link


      Navitor Pharmaceuticals
        web link


      NeuroVia


      Omada Health
        web link


      Ovid Therapeutics
        web link


      Proteostasis Therapeutics
        web link


      Science 37
        web link


      Selecta
        web link


      Ultragenyx
        web link


      Valerion Therapeutics
        web link


      Yumanity Therapeutics
        web link


     

    Recent News: